Advanced Prostate Cancer VL

Using Biomarkers to Determine When Biopsy and When to Repeat the Biopsy- Stephen Williams

Details
(Length of Discussion: 17 min) In this slide presentation, Stephen Williams details using biomarkers to determine when to biopsy and when to repeat a prostate biopsy specifically: PSA, PHI, 4K, PCA3 and Confirm MDx, He overviews the patient journey pre and post biopsy and the process of determining which patients need a rebiopsy. Biography: Stephen B. Williams, MD Assistant Professor in Urology, T...

Active Surveillance: Protecting Patients From Harm- Laurence Klotz

Details
Protecting Patients From Harm - Active Surveillance Biographies: Thomas E Keane Laurence Klotz, MD Related Content: Active Surveillance in PCa+ Active surveillance in prostate cancer: a critical review

IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer- Lorelei Mucci

Details
IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer Biographies: Alicia Morgans, MD, MPH Lorelei Mucci, ScD, MPH Also check out Lorelei Mucci & Philip Kantoff on Outcomes Research and the IRONMAN Project Related Content: Watch: IRONMAN - A Better Understanding of the Variation in Care and Treatment - Daniel George Watch: Lorelei Mucci and Philip Kantoff on O...

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer - Stacy Loeb

Details
(Length of discussion - 17 minutes) Medical or surgical castration are currently the mainstay of therapy for advanced prostate cancer. However, there is controversy regarding the association between testosterone replacement therapy (TRT) and advanced prostate cancer risk. Studies on this have been done in the past and the data was combined in a meta-analysis concluding that there is no increased r...

Debate: Comparative Effectiveness of Surgery versus Radiation- Laurence Klotz

Details
The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October. Laurence Klotz, MD and Mack Roach, III , MD presented a debate on “Comparative Effectiveness of Surgery and Radiation: Surgery Is Better” versus “Radiotherapy Yields Better Oncologic Outcomes than Radical Prostatectomy for Clin...

Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer- Karim Fizazi

Details
The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October. Karim Fizazi, MD presents, “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” and discusses mechanisms of resistance to ADT with CRPC, mechanisms of CRPC resistance to new drugs and mechanisms of resis...

ADT and the Mechanisms of Cardiovascular Disease- E. David Crawford

Details
The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6) E. David Crawford presents the potential mechanisms for differences in cardiovascular risk with different forms of ADT including; metabolic status, exacerbation of underlying cardiovascular disease (CVD) and preclinical data. In addition, a discussion on the need for the risk of CVD to be assessed...

Mack Roach and Martin Spahn on 'Oligometastases: RP is experimental and should only be done in the context of a prospective clinical trial’ versus 'RP and SBRT to bone disease is a reasonable manageme...

Details
Dr. Mack Roach and Dr. Martin Spahn presented a debate on “Oligometastases: RP Is Experimental and Should Only Be Done in the Context of a Prospective Clinical Trial” versus “RP and SBRT to Bone Disease Is a Reasonable Management Strategy for Men with Oligomets” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6) Biographies: Mack Roach III, MD Martin Spahn, MD , currently Senior Con...

Thomas Keane on Vitamin D and Prostate Cancer - STOP 6

Details
Prostate Cancer and Vitamin D (STOP 6) Biography: Thomas E. Keane, MBBCh, FRCSI, FACS

Piet Ost on The impact of local treatment of the prostate in patients with newly diagnosed metastatic prostate cancer - STOP 6

Details
The impact of local treatment of the prostate in patients with newly diagnosed metastatic prostate cancer (STOP 6) Biography: Piet Ost, MD, PhD is the adjunct head of the Radiation oncology clinic, part of the Ghent University Hospital. He is an assistant professor and part of the faculty of Medicie and Health Sciences at the University of Ghent. Dr. Ost is a member of the Steering Committee of IO...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe